Tiny Biotech Just Beat AbbVie's Drug: Risk for Investors?
A tiny biotech just beat AbbVie's blockbuster in early-stage results, prompting fresh questions about the durability ...
This brief explains the asset selection logic behind equal weighted indices and how different asset classes impact portfolio balance.
23,793 articlesA tiny biotech just beat AbbVie's blockbuster in early-stage results, prompting fresh questions about the durability ...
When insiders move stock, investors pay attention. This article breaks down what iradimed’s founder sold 7,500 means ...
Alphabet surged over the past year, but a 10% pullback from its high has investors wondering if now is the moment to ...
A CFO's $2.1 million sale of OUSTER shares raises questions for investors. This analysis explains what such insider m...
Cellebrite's CEO moved a sizable stake, selling 103,000 shares for about $1.6 million. This article breaks down what ...
A Tuesday surge in Uber stock sparked curiosity among investors. This article dives into the catalysts, profitability...
As AI demand soars, Micron sits at the center of memory hardware used in data centers. This article breaks down wheth...
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
This deep-dive breaks down veru (veru) 2026 earnings, translating the quarterly numbers into a clear sense of cash he...
Investors are keeping a close eye on Co-Diagnostics as 2025 earnings unfold. This guide breaks down what to look for ...
A director just bought more than 11,000 Ardent Health shares, sparking questions about the stock after this insider m...
When a CEO discloses a sale of 41,600 shares, investors pay attention. This article unpacks the implications, the mec...